Details

Autor(en) / Beteiligte

• Takahashi, Y
• Tomita, H
• Yasuda, K
• Kawai, M
• Yamamori, T
• Furuichi, N
• Misawa, K
• Ohashi, H

Titel

A case report of TS-1 in a patient with advanced gastric cancer

Ist Teil von

• Gan to kagaku ryoho, 2000-11, Vol.27 (13), p.2145

Ort / Verlag

Japan

Erscheinungsjahr

2000

Quelle

MEDLINE

Beschreibungen/Notizen

• TS-1 is an oral anticancer drug that produces biochemical modulation. TS-1 is composed of FT (tegafur), CDHP (gimestat, which inhibits 5-FU degradation enzyme), and Oxo (otastat potassium, which reduces 5-FU gastrointestinal toxicities), in a molar ratio of 1:0.4:1. We administered TS-1 to a 68-year-old female gastric cancer patient, after distal gastrectomy (Stage IV, cur C). As a result of abdominal CT, the diameter of metastatic lymph node increased before and after surgery, and before TS-1 (45 x 35 mm), but it was reduced after 1 course of TS-1 (37 x 25 mm), 2 courses of TS-1 (35 x 20 mm), 3 courses of TS-1 (30 x 20 mm), 4 courses of TS-1 (30 x 20 mm), and 6 months after 4 courses of TS-1 (20 x 20 mm). The reduction rate is 74.6%. The value of CA125 was reduced 74.4 to 8.6 after TS-1. Anorexia and back pain, which occurred after operation, disappeared after TS-1. There was no side effect over grade 3.